Marco J. Iafolla
Brampton, ON L6R3J7, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors.
Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors.
Journal: Current oncology (Toronto, Ont.)
Published: September 17, 2024
Point of Care Liquid Biopsy for Cancer Treatment-Early Experience from a Community Center.
Journal: Cancers
Published: June 11, 2024
Does Loosening the Inclusion Criteria of the CROSS Trial Impact Outcomes in the Curative-Intent Trimodality Treatment of Oesophageal and Gastroesophageal Cancer Patients?
Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: February 02, 2022
Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care.
Journal: Current oncology (Toronto, Ont.)
Published: January 17, 2022
A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre.
Journal: Current oncology (Toronto, Ont.)
Published: December 23, 2021
Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223.
Journal: Cancer medicine
Published: March 19, 2021
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity.
Journal: Nature communications
Published: October 09, 2020
Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis.
Journal: JNCI cancer spectrum
Published: February 13, 2020
Last Updated: 09/26/2026